UCB SA (UNC.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:UNC • BE0003739530
UNC.DE Key Statistics, Chart & Performance
The current stock price of UNC.DE is 262.4 EUR. In the past month the price increased by 8.97%.
UNC.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to UNC.DE.
UNC.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to UNC.DE. UNC.DE has only an average score on both its financial health and profitability.
UNC.DE Financial Highlights
Over the last trailing twelve months UNC.DE reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.45% | ||
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| Debt/Equity | 0.29 |
UNC.DE Forecast & Estimates
25 analysts have analysed UNC.DE and the average price target is 276.11 EUR. This implies a price increase of 5.22% is expected in the next year compared to the current price of 262.4.
For the next year, analysts expect an EPS growth of 60.25% and a revenue growth 25.37% for UNC.DE
UNC.DE Ownership
UNC.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.69 | 197.812B | ||
| SAN | SANOFI | 9.51 | 194.092B | ||
| SNW | SANOFI | 9.5 | 193.899B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| MRK | MERCK KGAA | 14.22 | 52.804B | ||
| UCB | UCB SA | 25.65 | 50.962B | ||
| BAYN | BAYER AG-REG | 9.43 | 44.995B | ||
| 1BAYN | BAYER AG-REG | 9.17 | 44.008B | ||
| IPN | IPSEN | 12.05 | 11.406B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About UNC.DE
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UNC.DE FAQ
Can you describe the business of UCB SA?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
What is the stock price of UCB SA today?
The current stock price of UNC.DE is 262.4 EUR. The price decreased by -0.64% in the last trading session.
What is the dividend status of UCB SA?
UCB SA (UNC.DE) has a dividend yield of 0.36%. The yearly dividend amount is currently 1.36.
How is the ChartMill rating for UCB SA?
UNC.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for UNC.DE stock?
25 analysts have analysed UNC.DE and the average price target is 276.11 EUR. This implies a price increase of 5.22% is expected in the next year compared to the current price of 262.4.
What is the next earnings date for UNC stock?
UCB SA (UNC.DE) will report earnings on 2026-02-26, after the market close.